| DERBEL, Olfa |
EMBER-4, NCT05514054: A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer |
|
|
| Recruiting | 3 | 6000 | Europe, Canada, Japan, US, RoW | Imlunestrant, LY3484356, Tamoxifen, Anastrozole, Letrozole, Exemestane | Eli Lilly and Company | Breast Neoplasms | 10/27 | 03/32 | | |
| Recruiting | 2 | 390 | Europe, Japan, RoW | Chemotherapy, Bevacizumab-Awwb, Niraparib | ARCAGY/ GINECO GROUP, GSK | Ovarian Cancer | 02/27 | 02/30 | | |
MOST plus, NCT02029001: Adapting Treatment to the Tumor Molecular Alterations for Patients With Advanced Solid Tumors: MyOwnSpecificTreatment |
|
|
| Recruiting | 2 | 900 | Europe | Nilotinib (400 mg BID), Open cohort, Everolimus (10 mg QD), Closed cohort, Sorafenib (400 mg BID), Lapatinib (1500 mg QD), Pazopanib (800 mg QD), Olaparib (300 mg BID), Durvalumab + Tremelimumab | Centre Leon Berard, National Cancer Institute, France | Malignant Solid Neoplasms | 01/26 | 10/27 | | |
| Active, not recruiting | 2 | 53 | Europe | Tucatinib, Pertuzumab, Perjeta®, Trastuzumab, Herceptin® or Biosimilar, Hormone therapy, Pertuzumab/ Trastuzumab, Phesgo® | UNICANCER, Seagen Inc., ARCAGY/ GINECO GROUP | Metastatic Breast Cancer With a Isolated Brain Progression | 04/25 | 04/26 | | |
| Active, not recruiting | 2 | 180 | Europe | OSE2101, TEDOPI®, Pembrolizumab 25 MG/ML [Keytruda], KEYTRUDA®, MK-3475 | ARCAGY/ GINECO GROUP, OSE Immunotherapeutics, Merck Sharp & Dohme LLC | Platinum-sensitive Ovarian Cancer, Relapsed Ovarian Cancer | 12/25 | 12/25 | | |
| Recruiting | 2 | 1100 | Europe | Ribociclib (neoadjuvant), Kisqali, Chemotherapy (adjuvant), Ribociclib (adjuvant) | SOLTI Breast Cancer Research Group, Novartis, UNICANCER | Breast Cancer Stage II | 08/28 | 07/30 | | |
ETNA, NCT06078384: Pembrolizumab and Chemotherapy Treatment or no Treatment Guided by the Level of TILs in Resected Early-stage TNBC |
|
|
| Recruiting | 2 | 354 | Europe | Pembrolizumab 25 mg/ml, keytruda, Paclitaxel injection, Taxol | UNICANCER, MSD France, SOLTI Breast Cancer Research Group, Gustave Roussy, Cancer Campus, Grand Paris, Vall Hebron Insitut Recerca | Triple-negative Breast Cancer | 12/31 | 12/31 | | |
| Recruiting | N/A | 420 | Europe | FASTRACS intervention | Hospices Civils de Lyon | Breast Cancer | 12/23 | 12/23 | | |
| Teixeira, Luis A |
EMBER-4, NCT05514054: A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer |
|
|
| Recruiting | 3 | 6000 | Europe, Canada, Japan, US, RoW | Imlunestrant, LY3484356, Tamoxifen, Anastrozole, Letrozole, Exemestane | Eli Lilly and Company | Breast Neoplasms | 10/27 | 03/32 | | |
SAFIR 03, NCT05625087: Detection of Tumor DNA in the Blood of Patients Receiving Standard Therapy for Hormone Receptor-positive (HR+) Non-HER2 Expressing (HER2-) Metastatic Breast Cancer as a Tool to Select Those Who May Benefit From the Next Course of Fulvestrant in Combination With Alpelisib or Ribociclib |
|
|
| Recruiting | 2 | 162 | Europe | Alpelisib, Fulvestrant, Ribociclib | UNICANCER, Novartis, Breast Cancer Research Foundation | Breast Cancer Stage IV | 07/28 | 06/30 | | |
| Recruiting | N/A | 500 | Europe | Data collection | Assistance Publique - Hôpitaux de Paris | Solid Tumor, Hematologic Malignancy, Thoracic Cancer, Cancer, Treatment-Related, Vaccine Response Impaired | 02/24 | 02/24 | | |
REPARP, NCT05378204: Study Evaluating DNA Double-strand Breaks (DSBs) REpair Factors (POLQ, Shieldin Complex and 53BP1) Expression as Biomarker of PARP Inhibitor Resistance in Patients With Deleterious Germline Mutation in BRCA 1/2 and HER2-negative, Metastatic or Locally Advanced Breast Cancer. |
|
|
| Recruiting | N/A | 120 | Europe | Main study:, Sub-study: | Institut Claudius Regaud, Artios Pharma Ltd | Breast Cancer | 01/27 | 06/27 | | |
| Recruiting | N/A | 4975 | Europe, RoW | RP-1828 IMMUcan, RP-1759 AYA/TYA, RP-1843 Arcagen, RP-1920 BioRadon | European Organisation for Research and Treatment of Cancer - EORTC | All Tumor Types | 03/26 | 03/26 | | |
ICRG0101, NCT04273542: Interest of Broadband Spectroscopy Analysis by Infrared Laser on Liquid Biopsies in Breast Cancer Screening |
|
|
| Active, not recruiting | N/A | 1100 | Europe | liquid biopsy | Centre Jean Perrin, International Cancer Research Group, Institut Max Planck d'optique quantique | Breast Cancer Female, BRCA1 Mutation, BRCA2 Mutation | 05/29 | 05/29 | | |
| BROCARD, Fabien |
| Active, not recruiting | 3 | 464 | Europe, RoW | FOLFIRI-cetuximab, mFOLFOX6-bevacizumab, OPTIMOX-bevacizumab, irinotecan-based chemo + bevacizumab, Anti-EGFR agent (cetuximab +/- irinotecan or panitumumab), XELOX + bevacizumab | GERCOR - Multidisciplinary Oncology Cooperative Group, Hoffmann-La Roche | Colorectal Cancer Metastatic | 07/23 | 12/24 | | |
| Recruiting | 3 | 260 | Europe, Canada, Japan, RoW | Carboplatin-Paclitaxel, Dostarlimab | ARCAGY/ GINECO GROUP, GlaxoSmithKline | Endometrial Cancer | 04/26 | 10/29 | | |
EMBER-4, NCT05514054: A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer |
|
|
| Recruiting | 3 | 6000 | Europe, Canada, Japan, US, RoW | Imlunestrant, LY3484356, Tamoxifen, Anastrozole, Letrozole, Exemestane | Eli Lilly and Company | Breast Neoplasms | 10/27 | 03/32 | | |
| Recruiting | 2 | 390 | Europe, Japan, RoW | Chemotherapy, Bevacizumab-Awwb, Niraparib | ARCAGY/ GINECO GROUP, GSK | Ovarian Cancer | 02/27 | 02/30 | | |
OPTIPRIME, NCT03584711: FOLFOX + Panitumumab According to a "Stop and go" Strategy With a Reintroduction Loop After Progression on Fluoropyrimidine as Maintenance Treatment, as the First Line in Patients With Metastatic Colorectal Adenocarcinoma Without a RAS Mutation |
|
|
| Active, not recruiting | 2 | 118 | Europe, RoW | FOLFOX + panitumumab | Federation Francophone de Cancerologie Digestive, Amgen | Metastatic Colorectal Cancer | 12/24 | 12/24 | | |
POCHI, NCT04262687: Chemotherapy and Immunotherapy as Treatment for MSS Metastatic Colorectal Cancer With High Immune Infiltrate |
|
|
| Recruiting | 2 | 55 | Europe | Capecitabine, Oxaliplatin, Bevacizumab, Pembrolizumab | Federation Francophone de Cancerologie Digestive | Colorectal Cancer Metastatic, High Immune Infiltrate, Microsatellite Stable | 09/24 | 09/24 | | |
| MOREAU, LIONEL |
PROMETHEE, NCT06646471: PROspective Master-protocol for Evaluation of Systemic THErapeutics in Elderly With Thoracic Malignancies |
|
|
| Recruiting | 4 | 500 | Europe | Bio-bank repository, Quality of Life (QoL), G-Code | Groupe Francais De Pneumo-Cancerologie | Non Small Cell Lung Cancer, Lung Cancer | 08/26 | 08/28 | | |
ELDERLY, NCT03977194: Atezolizumab in Elderly Patients With Advanced Non-Small-Cell Lung Cancer and Receiving Carboplatin Paclitaxel Chemotherapy |
|
|
| Active, not recruiting | 3 | 500 | Europe | Carboplatin, Paclitaxel, Atezolizumab | Intergroupe Francophone de Cancerologie Thoracique | Non Small Cell Lung Cancer Metastatic | 12/24 | 12/26 | | |
EMBER-4, NCT05514054: A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer |
|
|
| Recruiting | 3 | 6000 | Europe, Canada, Japan, US, RoW | Imlunestrant, LY3484356, Tamoxifen, Anastrozole, Letrozole, Exemestane | Eli Lilly and Company | Breast Neoplasms | 10/27 | 03/32 | | |
DIAL, NCT05255302 / 2021-006044-27: De-escalation Immunotherapy MAintenance Duration Trial for Stage IV Lung Cancer Patients with Disease Control After Chemo-immunotherapy Induction |
|
|
| Recruiting | 2/3 | 1360 | Europe | Pembrolizumab before randomization, Chemotherapy, Pemetrexed, Pembrolizumab after randomization | Intergroupe Francophone de Cancerologie Thoracique, IFCT | Metastatic NSCLC | 01/25 | 06/29 | | |
ORBITAL, NCT04233021: Study of Osimertinib in Patients with a Lung Cancer with Brain or Leptomeningeal Metastases with EGFR Mutation |
|
|
| Active, not recruiting | 2 | 57 | Europe | Osimertinib | Intergroupe Francophone de Cancerologie Thoracique | Non Small Cell Lung Cancer Metastatic, Leptomeningeal Metastasis, Brain Metastases, EGFR Activating Mutation | 03/23 | 12/24 | | |
| Active, not recruiting | 2 | 50 | Europe | Durvalumab | Intergroupe Francophone de Cancerologie Thoracique, IFCT, AstraZeneca | Non-small Cell Lung Cancer Stage IV | 11/23 | 10/25 | | |
ORAKLE, NCT04111705: Lorlatinib After Failure of First-line Second-generation ALK Kinase Inhibitor in Patients with Advanced ALK-positive Non-small Cell Lung Cancer |
|
|
| Active, not recruiting | 2 | 23 | Europe | Lorlatinib | Intergroupe Francophone de Cancerologie Thoracique | Non Small Cell Lung Cancer Metastatic | 01/25 | 01/25 | | |
| Recruiting | 2 | 119 | Europe | Encorafenib 75 MG, Binimetinib 15 MG | Intergroupe Francophone de Cancerologie Thoracique, IFCT, Pierre Fabre | Non Small Cell Lung Cancer, BRAF V600E | 12/24 | 03/26 | | |
|
REPOROS, NCT06552234: Phase II Efficacy Study of Repotrectinib in Frail and/or Elderly Patients With ROS1-rearranged Advanced NSCLC |
|
|
| Not yet recruiting | 2 | 30 | Europe | Repotrectinib | Centre Hospitalier Intercommunal de Toulon La Seyne sur Mer, Groupe Français de Pneumo-Cancérologie, Hospices Civils de Lyon | NSCLC Stage IV, NSCLC, Stage III | 09/31 | 09/31 | | |
NCT04621188: Lorlatinib After Failure of First-line TKI in Patients with Advanced ROS1-positive NSCLC (ALBATROS) |
|
|
| Recruiting | 2 | 84 | Europe | Lorlatinib | Intergroupe Francophone de Cancerologie Thoracique | Non Small Cell Lung Cancer Metastatic | 03/25 | 01/26 | | |
ADAPTABLE, NCT05781308: Combination of Paclitaxel-bevacizumab ± Atezolizumab in Patients with Advanced NSCLC Progressing After Immunotherapy & Chemotherapy |
|
|
| Active, not recruiting | 2 | 156 | Europe | Paclitaxel, Bevacizumab, Avastin, Atezolizumab, Tecentriq | Intergroupe Francophone de Cancerologie Thoracique | Non Small Cell Lung Cancer | 09/25 | 06/26 | | |
TAXIO, NCT05856695: A Phase II Study Assessing the Efficacy of Etoposide Free Chemotherapy Plus Durvalumab (MEDI4736) in First Line Extensive Disease Small Cell Lung Cancer (SCLC) |
|
|
| Recruiting | 2 | 67 | Europe | Carboplatin + Paclitaxel + Durvalumab | Intergroupe Francophone de Cancerologie Thoracique | Small Cell Lung Cancer Extensive Stage | 02/26 | 02/28 | | |
SAFIR 03, NCT05625087: Detection of Tumor DNA in the Blood of Patients Receiving Standard Therapy for Hormone Receptor-positive (HR+) Non-HER2 Expressing (HER2-) Metastatic Breast Cancer as a Tool to Select Those Who May Benefit From the Next Course of Fulvestrant in Combination With Alpelisib or Ribociclib |
|
|
| Recruiting | 2 | 162 | Europe | Alpelisib, Fulvestrant, Ribociclib | UNICANCER, Novartis, Breast Cancer Research Foundation | Breast Cancer Stage IV | 07/28 | 06/30 | | |
ETNA, NCT06078384: Pembrolizumab and Chemotherapy Treatment or no Treatment Guided by the Level of TILs in Resected Early-stage TNBC |
|
|
| Recruiting | 2 | 354 | Europe | Pembrolizumab 25 mg/ml, keytruda, Paclitaxel injection, Taxol | UNICANCER, MSD France, SOLTI Breast Cancer Research Group, Gustave Roussy, Cancer Campus, Grand Paris, Vall Hebron Insitut Recerca | Triple-negative Breast Cancer | 12/31 | 12/31 | | |
NCT04720339: Molecular Monitoring of cfDNA by ddPCR in Non-small Cell Lung Cancer Treated by Immunotherapy. |
|
|
| Recruiting | N/A | 250 | Europe | Molecular monitoring by quantification of cell-free DNA | University Hospital, Strasbourg, France | NSCLC, IMMUNOTHERAPY, QUANTIFICATION OF CELL-FREE DNA | 05/25 | 10/27 | | |
ROSIE, NCT06053099: A Prospective Cohort Study to Evaluate Molecular pRognostic Factors and Resistance Mechanisms to Osimertinib in Adjuvant Treatment of Completely Resected pIB-IIIA Non-small Cell Lung Carcinoma With Common EGFR Mutations (L858R and Del19) |
|
|
| Recruiting | N/A | 300 | Europe | Plasma ctDNA, FFPE blocks | Intergroupe Francophone de Cancerologie Thoracique | Non Small Cell Lung Cancer, EGFR Activating Mutation, EGFR DEL19, EGFR L858R | 10/31 | 10/31 | | |
| Saito, Tsuyoshi |
NCT04063527: Phase III Trial of Stage I Ovarian Cancer After Surgery |
|
|
| Recruiting | 3 | 360 | Japan, RoW | adjuvant chemotherapy, paclitaxel and carboplatin | Japanese Gynecologic Oncology Group, Korean Gynecologic Oncology Group | Epithelial Ovarian Cancer | 10/29 | 02/30 | | |
| 赤坂, Keiichi 圭一 Akasaka |
| Active, not recruiting | 3 | 160 | Europe, Canada, Japan, US, RoW | Molgramostim, Recombinant human granulocyte-macrophage colony stimulating factor (rhGM-CSF), Placebo | Savara Inc., Savara ApS, | Autoimmune Pulmonary Alveolar Proteinosis | 11/23 | 11/24 | | |
| Bailleux, Caroline |
EMBER-4, NCT05514054: A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer |
|
|
| Recruiting | 3 | 6000 | Europe, Canada, Japan, US, RoW | Imlunestrant, LY3484356, Tamoxifen, Anastrozole, Letrozole, Exemestane | Eli Lilly and Company | Breast Neoplasms | 10/27 | 03/32 | | |
| Active, not recruiting | 2 | 53 | Europe | Tucatinib, Pertuzumab, Perjeta®, Trastuzumab, Herceptin® or Biosimilar, Hormone therapy, Pertuzumab/ Trastuzumab, Phesgo® | UNICANCER, Seagen Inc., ARCAGY/ GINECO GROUP | Metastatic Breast Cancer With a Isolated Brain Progression | 04/25 | 04/26 | | |
ETIC-LM, NCT05800275: Capecitabine, Tucatinib, and Intrathecal Trastuzumab for Breast Cancer Patients with Leptomeningeal Disease |
|
|
| Recruiting | 2 | 30 | NA | Tucatinib Oral Tablet, Capecitabine tablets, Trastuzumab Injection | UNICANCER, Seagen Inc. | Leptomeningeal Metastasis, Leptomeningeal Disease, HER2-positive Metastatic Breast Cancer | 12/26 | 06/27 | | |
SAFIR 03, NCT05625087: Detection of Tumor DNA in the Blood of Patients Receiving Standard Therapy for Hormone Receptor-positive (HR+) Non-HER2 Expressing (HER2-) Metastatic Breast Cancer as a Tool to Select Those Who May Benefit From the Next Course of Fulvestrant in Combination With Alpelisib or Ribociclib |
|
|
| Recruiting | 2 | 162 | Europe | Alpelisib, Fulvestrant, Ribociclib | UNICANCER, Novartis, Breast Cancer Research Foundation | Breast Cancer Stage IV | 07/28 | 06/30 | | |
CALHYS, NCT05664893: Study to Determine the Safety and Efficacy of Ribociclib in Combination With Hormone Therapy and Hypofractionated Radiotherapy in Breast Cancer, With Positive Hormone Receptors and Negative HER2 Status, in Newly Diagnosed, Not Immediately Operable Elderly Patient |
|
|
| Recruiting | 1/2 | 85 | Europe | Ribociclib Oral Tablet | Centre Antoine Lacassagne | HER2 Negative Breast Cancer Not Immediately Operated | 10/31 | 03/33 | | |
ARIANE, NCT06400849: Comparison of the Efficacy of Cryotherapy Combined With Compression in Preventing Neuropathy |
|
|
| Recruiting | N/A | 60 | Europe | cryotherapy alone of the upper or lower limbs, cryotherapy and crompression of the upper or lower limbs | Centre Antoine Lacassagne, Thuasne | Non-metastatic Breast Cancer | 12/26 | 06/27 | | |
| Higuchi, Toru |
EMBER-4, NCT05514054: A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer |
|
|
| Recruiting | 3 | 6000 | Europe, Canada, Japan, US, RoW | Imlunestrant, LY3484356, Tamoxifen, Anastrozole, Letrozole, Exemestane | Eli Lilly and Company | Breast Neoplasms | 10/27 | 03/32 | | |
| Ishii, Kiyoshi |
NCT06116916: Study to Assess the Efficacy & Safety of KHK4951 in Patients With Diabetic Macular Edema |
|
|
| Recruiting | 2 | 150 | Japan, US, RoW | KHK4951, Aflibercept Injection | Kyowa Kirin Co., Ltd. | Diabetic Macular Edema (DME) | 11/25 | 12/25 | | |
NCT06116890: Study to Assess the Efficacy & Safety of KHK4951 in Patients With Neovascular Age-Related Macular Degeneration |
|
|
| Recruiting | 2 | 180 | Japan, US, RoW | KHK4951, Aflibercept Injection | Kyowa Kirin Co., Ltd. | Neovascular Age-Related Macular Degeneration (nAMD) | 11/25 | 12/25 | | |
| Honda, Shigeru |
NCT06116916: Study to Assess the Efficacy & Safety of KHK4951 in Patients With Diabetic Macular Edema |
|
|
| Recruiting | 2 | 150 | Japan, US, RoW | KHK4951, Aflibercept Injection | Kyowa Kirin Co., Ltd. | Diabetic Macular Edema (DME) | 11/25 | 12/25 | | |
NCT06116890: Study to Assess the Efficacy & Safety of KHK4951 in Patients With Neovascular Age-Related Macular Degeneration |
|
|
| Recruiting | 2 | 180 | Japan, US, RoW | KHK4951, Aflibercept Injection | Kyowa Kirin Co., Ltd. | Neovascular Age-Related Macular Degeneration (nAMD) | 11/25 | 12/25 | | |
| Hoshino, Kota |
J-NEURO, NCT06776549: Hypothermia Versus Normothermia After Extracorporeal Cardiopulmonary Resuscitation for Out-of-hospital Cardiac Arrest |
|
|
| Recruiting | N/A | 468 | Japan | Temperature control | Kagawa University | Out-of-hospital Cardiac Arrest (OHCA), ECMO Treatment, Temperature, Post Cardiac Arrest Syndrome | 12/27 | 12/28 | | |
